BƯỚC ĐẦU ĐÁNH GIÁ HIỆU QUẢ ĐIỀU TRỊ LIỆU PHÁP ỨC CHẾ MIỄN DỊCH TRÊN NGƯỜI BỆNH SUY TỦY DÒNG HỒNG CẦU MẮC PHẢI TẠI BỆNH VIỆN TRUYỀN MÁU HUYẾT HỌC
Objective: To describe the clinical and laboratory characteristics of patients with acquired pure red cell aplasia (PRCA) and to evaluate the initial efficacy and safety of immunosuppressive therapy (IST).Subjects and methods: We conducted a retrospective case-series study of patients with acquired PRCA treated at the Blood Transfusion and Hematology Hospital, Ho Chi Minh City, Vietnam, between January 2018 and December 2025.Results: The study included 23 patients with acquired PRCA, with a median age of 47 years (range, 26–79), of whom 65.2% were female. Secondary PRCA accounted for 65.2% of cases; T-cell large granular lymphocytic leukemia (T-LGLL) was the most common underlying cause (34.8%), followed by thymoma (17.4%). Eighteen patients received immunosuppressive therapy (IST). The overall response rates to IST were 77.8% in the first-line setting and 75.0% in the second-line setting. Cyclosporine A (CsA) was the most commonly used agent, achieving a first-line overall response rate of 77.8% as monotherapy and 100% when used in combination regimens. After a median follow-up of 22.3 months, the relapse-free survival rate was 84.8%.Conclusion: CsA-based IST, whether administered as monotherapy or in combination, demonstrated favorable preliminary efficacy, with first-line response rates exceeding 70%; responses were generally maintained during follow-up, although 3 relapses occurred. Treatment-related toxicities were manageable in patients with acquired PRCA.
Authors
- Chí Dũng Phù
- Nguyễn Văn Tài
- Thiện Ngôn Huỳnh
- Lê Quốc Vũ Trịnh
- Thị Thu Hiền Đào
Institutions
- University of Medicine and Pharmacy at Ho Chi Minh City (VN)
Publication Details
- Journal
- Journal of Clinical Medicine Bach Mai Hospital
- Published
- 2026-11-21
- DOI
- https://doi.org/10.52322/jocmbmh.156.0213
- Primary Topic
- Hematological disorders and diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00